Risk of Thromboembolism in Women Taking Ethinylestradiol/Drospirenone and Other Oral Contraceptives
| Autor: | Jeanne Loughlin, C. Robin Clifford, Alexander M. Walker, Jennifer A. Cutone, P. Mona Eng, John D. Seeger |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent medicine.drug_class Population Physiology Ethinyl Estradiol Risk Assessment Cohort Studies Risk Factors Oral administration Thromboembolism Ethinylestradiol medicine Humans Child education Proportional Hazards Models Gynecology education.field_of_study business.industry Obstetrics and Gynecology Drospirenone Middle Aged Contraceptives Oral Combined Estrogen Family planning Androstenes Female Risk assessment business Progestin Follow-Up Studies medicine.drug |
| Zdroj: | Obstetrics & Gynecology. 110:587-593 |
| ISSN: | 0029-7844 |
| DOI: | 10.1097/01.aog.0000279448.62221.a8 |
| Popis: | The oral contraceptive ethinylestradiol 0.03 mg/drospirenone 3 mg contains a progestin component that differs from other oral contraceptives. Case reports and prescription event monitoring suggested that ethinylestradiol/drospirenone might be associated with an elevated risk of thromboembolism. We sought to estimate the association between ethinylestradiol/drospirenone and risk of thromboembolism relative to the association among other oral contraceptives.We identified ethinylestradiol/drospirenone initiators and a twofold larger group of other oral contraceptive initiators between June 2001 and June 2004 within a U.S. health insurer database. The comparison group was selected to have demographic and health care characteristics preceding oral contraceptive initiation that were similar to ethinylestradiol/drospirenone initiators. Thromboembolism during the follow-up of the cohorts was identified through claims for medical services, and only medical record-confirmed cases were included in analyses. The primary (as-matched) analysis used proportional hazards regression, whereas a secondary (as-treated) analysis accounted for changes in oral contraceptives during follow-up using Poisson regression.The 22,429 ethinylestradiol/drospirenone initiators and 44,858 other oral contraceptive initiators were followed for an average of 7.6 months, and there were 18 cases of thromboembolism in ethinylestradiol/drospirenone initiators and 39 in the comparators (rate ratio 0.9, 95% confidence interval 0.5-1.6). More than 9,000 women would need to be prescribed oral contraceptives to observe a difference of one case of thromboembolism. Results of the as-treated analysis were similar to those of the as-matched analysis.Ethinylestradiol/drospirenone initiators and initiators of other oral contraceptives are similarly likely to experience thromboembolism.II. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|